Athira Pharma, Inc., a Seattle, WA-based clinical-stage company developing innovative first-in-class regenerative therapies with the potential to restore brain function, closed an $85m Series B financing.
The round was led by Perceptive Advisors with participation from new investors RTW Investments, Viking Global Investors, Venrock Healthcare Capital Partners, Franklin Templeton, Rock Springs Capital, LifeSci Venture Partners, Surveyor Capital (a Citadel company), Highside Capital Management, Logos Capital, funds managed by Janus Henderson Investors, Sofinnova Investments, Avidity Partners, and existing investors including Rick and Suzanne Kayne and Sahsen Ventures.
The company intends to use the funds to support a Phase 2/3 Alzheimer’s clinical trial of NDX-1017.
Led by Dr. Leen Kawas, President and Chief Executive Officer, Athira is a clinical stage drug development company improving human health by advancing bold and innovative therapies with the potential to restore the lives of people impacted by brain disorders. It is currently advancing its lead therapeutic candidate, NDX-1017, a novel small molecule, in later-stage clinical trials for Alzheimer’s.